AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch
November 07 2022 - 8:01AM
Business Wire
Official US rollout kicks off with coveted
award from Cosmopolitan Magazine and new $99/month* patient
financing options
Cutera, Inc. (Nasdaq: CUTR) ("Cutera" or the "Company"), a
leading provider of aesthetic and dermatology solutions, today
announces that AviClear is now broadly available to physicians and
practitioners treating patients throughout North America. AviClear
is the first and only energy device to be both FDA cleared and
Health Canada approved for the treatment of mild, moderate, and
severe acne, with additional approval in Canada for acne scars.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221107005473/en/
(Graphic: Business Wire)
AviClear has seen widespread interest from physicians and
patients following its FDA clearance in March 2022, and was
recently awarded the “Best Laser Treatment for Acne” by
Cosmopolitan Magazine. In conjunction with greater availability,
Cutera is also announcing a new, monthly financing plan to US
consumers starting at $99 a month*.
“I was an early AviClear adopter because I know this treatment
will change the way my acne patients face the world,” said Sonia
Batra, MD, founder of Batra Dermatology. “I am thrilled my
colleagues nationwide will now have access to this device, and I am
even happier for their patients who have not wanted or could not
proceed with prescription options. What makes the treatment even
more appealing is that it can be used on all skin types and acne
severities without adverse effects. I have no doubt it will be the
treatment of choice for many acne sufferers.”
“We are pleased to see AviClear praised as a groundbreaking
treatment by physicians, patients, and the media,” said Dave Mowry,
CEO of Cutera. “Pairing the commercial launch with the new patient
financing option will enable us to extend the reach of AviClear to
more people who want an effective, chemical-free, and durable
solution to their acne.
“Based on our market feedback to date, we are confident that
patient demand and practice installations will continue to grow
over the next several quarters beginning in the first quarter of
2023,” said Mowry. “Affordability, efficacy, and durability will
help establish AviClear as the gold standard of care for acne
suffers.”
AviClear is now broadly available to physicians and
practitioners across the United States, with a limited commercial
release in Canada. Doctors and patients are encouraged to visit
www.AviClear.com to find out more information.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of
aesthetic and dermatology solutions for practitioners worldwide.
Since 1998, Cutera has been developing innovative, easy-to-use
products that harness the power of science and nature to enable
medical practitioners to offer safe and effective treatments to
their patients. For more information, call +1 415-657-5500 or
1-888-4CUTERA or visit www.cutera.com.
*Terms and conditions apply.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107005473/en/
PR Contact: EvolveMKD, Cutera@EvolveMKD.com
Investor Relations: Greg Barker, VP of FP & A –
IR@cutera.com
Cutera (NASDAQ:CUTR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cutera (NASDAQ:CUTR)
Historical Stock Chart
From Jul 2023 to Jul 2024